GREENWICH, Conn., Aug. 31 /PRNewswire/ -- Mederi Therapeutics Inc. announces the US release of the Secca system for treatment of bowel incontinence. Secca Therapy is a minimally invasive procedure for a debilitating and embarrassing condition that affects tens of millions of Americans, both young and old. Secca therapy delivers radiofrequency (RF) energy to the muscles of the anal canal - tightening the muscles, producing better bowel control and reducing the symptoms of incontinence.
"This innovative treatment bridges the gap between often unsuccessful conservative measures, such as diet modification and biofeedback, and expensive and disfiguring surgical treatment," said Mederi CEO, Will Rutan. "The effect of bowel incontinence on quality of life is devastating, so the overwhelmingly positive response to the release of the Secca system is not surprising."
Secca therapy is an outpatient procedure that takes approximately 45 minutes and is performed in an endoscopy suite or ambulatory surgery unit, with the patient under general anesthesia or conscious sedation. Patients go home approximately one to two hours after the procedure and, typically, resume normal activities within several days. In clinical trials as many as 8 out of 10 patients had a positive clinical response to Secca therapy and showed significant improvement in quality of life scores. Further, recent clinical studies have shown symptom relief lasting as long as five years.
The dominant cause of bowel incontinence is damage to the pelvic floor during normal childbirth, thus, a significant majority of sufferers are women, seventy percent of whom are under the age of 65. In the elderly, bowel incontinence is cited as the second leading reason to institutionalize loved ones and over 45 percent of residents in nursing homes suffer from this condition.
Due to the embarrassment associated with bowel incontinence, studies report that fewer than one in five people with this condition have discussed it with their doctors. These factors indicate that bowel incontinence is both a well-guarded and under-reported illness.
Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.
Contact: Sheila Doyle Manager of Communications and Marketing 203 930 9980
|SOURCE Mederi Therapeutics Inc.|
Copyright©2009 PR Newswire.
All rights reserved